1.73
price down icon0.57%   -0.01
 
loading
Schlusskurs vom Vortag:
$1.74
Offen:
$1.75
24-Stunden-Volumen:
2.57M
Relative Volume:
0.52
Marktkapitalisierung:
$258.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.07M
KGV:
-0.1237
EPS:
-13.99
Netto-Cashflow:
$-12.56M
1W Leistung:
+5.49%
1M Leistung:
-8.47%
6M Leistung:
+113.37%
1J Leistung:
+67.96%
1-Tages-Spanne:
Value
$1.72
$1.84
1-Wochen-Bereich:
Value
$1.60
$1.84
52-Wochen-Spanne:
Value
$0.53
$2.64

Palisade Bio Inc Stock (PALI) Company Profile

Name
Firmenname
Palisade Bio Inc
Name
Telefon
(858) 704-4900
Name
Adresse
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PALI's Discussions on Twitter

Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PALI
Palisade Bio Inc
1.73 259.61M 0 -14.07M -12.56M -13.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
491.47 117.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
803.17 82.85B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
821.96 51.58B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.40 40.75B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.07 38.33B 4.98B 69.60M 525.67M 0.5198

Palisade Bio Inc Stock (PALI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-01-09 Eingeleitet B. Riley Securities Buy
2025-12-29 Eingeleitet Piper Sandler Overweight

Palisade Bio Inc Aktie (PALI) Neueste Nachrichten

pulisher
Feb 13, 2026

Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com

Feb 13, 2026
pulisher
Feb 13, 2026

Palisade Bio CEO Finley sells $6818 in shares - Investing.com

Feb 13, 2026
pulisher
Feb 13, 2026

Can Palisade Bio Inc. maintain sales growthJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru

Feb 13, 2026
pulisher
Feb 09, 2026

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewswire

Feb 09, 2026
pulisher
Feb 07, 2026

Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat

Feb 07, 2026
pulisher
Feb 06, 2026

Aug Shorts: Will Palisade Bio Inc outperform its industry peers2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 05, 2026

Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 05, 2026

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com

Feb 05, 2026
pulisher
Feb 04, 2026

Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus

Feb 04, 2026
pulisher
Feb 04, 2026

Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN

Feb 04, 2026
pulisher
Feb 03, 2026

Can Palisade Bio Inc maintain sales growth2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 01, 2026

Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN

Feb 01, 2026
pulisher
Jan 29, 2026

Palisade Bio appoints two IBD experts to clinical advisory board By Investing.com - Investing.com South Africa

Jan 29, 2026
pulisher
Jan 29, 2026

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board - markets.businessinsider.com

Jan 29, 2026
pulisher
Jan 29, 2026

Palisade Bio appoints two IBD experts to clinical advisory board - Investing.com

Jan 29, 2026
pulisher
Jan 29, 2026

Two IBD leaders join Palisade Bio push on PALI-2108 for colitis and Crohn's - stocktitan.net

Jan 29, 2026
pulisher
Jan 26, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Jan 26, 2026
pulisher
Jan 26, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Jan 26, 2026
pulisher
Jan 25, 2026

MACD Signal: Does Palisade Bio Inc have declining or rising EPSWeekly Profit Recap & Risk Managed Investment Strategies - baoquankhu1.vn

Jan 25, 2026
pulisher
Jan 25, 2026

Portfolio Update: Is CINGW a potential multi baggerInflation Watch & Stepwise Trade Execution Plans - baoquankhu1.vn

Jan 25, 2026
pulisher
Jan 23, 2026

Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Jan 23, 2026
pulisher
Jan 19, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December - MarketBeat

Jan 19, 2026
pulisher
Jan 18, 2026

Published on: 2026-01-19 10:30:24 - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 17, 2026

Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 17, 2026

Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 16, 2026

Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com

Jan 16, 2026
pulisher
Jan 16, 2026

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice

Jan 16, 2026
pulisher
Jan 14, 2026

Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq

Jan 14, 2026
pulisher
Jan 14, 2026

Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com Nigeria

Jan 14, 2026
pulisher
Jan 13, 2026

Palisade Bio director Williams buys $9,400 in shares - Investing.com

Jan 13, 2026
pulisher
Jan 12, 2026

Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn

Jan 12, 2026
pulisher
Jan 10, 2026

Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn

Jan 10, 2026
pulisher
Jan 09, 2026

PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus

Jan 09, 2026
pulisher
Jan 09, 2026

B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com

Jan 09, 2026
pulisher
Jan 09, 2026

B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com

Jan 09, 2026
pulisher
Jan 09, 2026

B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com India

Jan 09, 2026
pulisher
Jan 08, 2026

How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria

Jan 08, 2026
pulisher
Jan 07, 2026

How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда

Jan 07, 2026
pulisher
Jan 07, 2026

Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - Bộ Nội Vụ

Jan 07, 2026
pulisher
Jan 07, 2026

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108 - The Manila Times

Jan 07, 2026

Finanzdaten der Palisade Bio Inc-Aktie (PALI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Palisade Bio Inc-Aktie (PALI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Finley John David
CEO, CFO
Feb 12 '26
Sale
1.75
3,896
6,818
27,353
Williams Donald Allen
Director
Jan 16 '26
Buy
1.67
5,000
8,356
10,728
Williams Donald Allen
Director
Jan 09 '26
Buy
1.88
5,000
9,400
5,728
$26.45
price down icon 1.12%
$45.19
price up icon 0.87%
$101.10
price up icon 0.35%
$105.87
price up icon 0.10%
$148.75
price up icon 1.77%
biotechnology ONC
$346.07
price down icon 0.10%
Kapitalisierung:     |  Volumen (24h):